CO2023016596A2 - Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo - Google Patents
Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxiloInfo
- Publication number
- CO2023016596A2 CO2023016596A2 CONC2023/0016596A CO2023016596A CO2023016596A2 CO 2023016596 A2 CO2023016596 A2 CO 2023016596A2 CO 2023016596 A CO2023016596 A CO 2023016596A CO 2023016596 A2 CO2023016596 A2 CO 2023016596A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical composition
- indol
- pyrazole
- cyano
- isopropyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000001431 Hyperuricemia Diseases 0.000 abstract 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
RESUMEN La presente invención se refiere a una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable del mismo, y a un método para tratar o prevenir una enfermedad relacionada con la hiperuricemia. enfermedad usando la misma, y la composición farmacéutica de la presente invención puede reducir eficazmente la concentración de ácido úrico en sangre en un paciente con una enfermedad relacionada con hiperuricemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210077709 | 2021-06-15 | ||
| PCT/KR2022/008450 WO2022265382A1 (ko) | 2021-06-15 | 2022-06-15 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023016596A2 true CO2023016596A2 (es) | 2023-12-11 |
Family
ID=84525806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0016596A CO2023016596A2 (es) | 2021-06-15 | 2023-11-30 | Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo |
| CONC2023/0016621A CO2023016621A2 (es) | 2021-06-15 | 2023-11-30 | Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0016621A CO2023016621A2 (es) | 2021-06-15 | 2023-11-30 | Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20240285583A1 (es) |
| EP (2) | EP4360631A4 (es) |
| JP (2) | JP2024520150A (es) |
| KR (2) | KR20220168173A (es) |
| CN (2) | CN117412746A (es) |
| AR (1) | AR126153A1 (es) |
| AU (2) | AU2022292402A1 (es) |
| BR (2) | BR112023026432A2 (es) |
| CA (2) | CA3221017A1 (es) |
| CL (2) | CL2023003513A1 (es) |
| CO (2) | CO2023016596A2 (es) |
| MX (2) | MX2023014359A (es) |
| PE (2) | PE20240242A1 (es) |
| PH (1) | PH12023553231A1 (es) |
| TW (1) | TWI888729B (es) |
| WO (2) | WO2022265378A1 (es) |
| ZA (2) | ZA202311241B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003647B2 (en) * | 2007-04-11 | 2011-08-23 | Kissei Pharmaceutical Co., Ltd. | (Aza)indole derivative and use thereof for medical purposes |
| TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| WO2014194226A2 (en) * | 2013-05-31 | 2014-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treatment and compositions with xanthine oxidase inhibitors |
| JP2015160847A (ja) * | 2014-02-28 | 2015-09-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 小分子のキサンチンオキシダーゼ阻害剤および使用方法 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| KR20210069685A (ko) * | 2018-10-01 | 2021-06-11 | 아스트라제네카 아베 | 혈청 요산을 감소시키기 위한 조성물 |
| EP4257123A4 (en) * | 2020-12-01 | 2024-05-08 | Lg Chem, Ltd. | STABLE ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID |
-
2022
- 2022-06-15 CN CN202280034026.0A patent/CN117412746A/zh active Pending
- 2022-06-15 EP EP22825301.9A patent/EP4360631A4/en active Pending
- 2022-06-15 WO PCT/KR2022/008444 patent/WO2022265378A1/ko not_active Ceased
- 2022-06-15 PE PE2023003221A patent/PE20240242A1/es unknown
- 2022-06-15 CA CA3221017A patent/CA3221017A1/en active Pending
- 2022-06-15 JP JP2023574689A patent/JP2024520150A/ja not_active Ceased
- 2022-06-15 AU AU2022292402A patent/AU2022292402A1/en not_active Abandoned
- 2022-06-15 MX MX2023014359A patent/MX2023014359A/es unknown
- 2022-06-15 EP EP22825305.0A patent/EP4344701A4/en not_active Withdrawn
- 2022-06-15 KR KR1020220072509A patent/KR20220168173A/ko not_active Ceased
- 2022-06-15 AR ARP220101577A patent/AR126153A1/es not_active Application Discontinuation
- 2022-06-15 BR BR112023026432A patent/BR112023026432A2/pt unknown
- 2022-06-15 BR BR112023026415A patent/BR112023026415A2/pt unknown
- 2022-06-15 PH PH1/2023/553231A patent/PH12023553231A1/en unknown
- 2022-06-15 TW TW111122220A patent/TWI888729B/zh active
- 2022-06-15 US US18/569,571 patent/US20240285583A1/en active Pending
- 2022-06-15 WO PCT/KR2022/008450 patent/WO2022265382A1/ko not_active Ceased
- 2022-06-15 CN CN202280039108.4A patent/CN117425477A/zh active Pending
- 2022-06-15 KR KR1020220072501A patent/KR20220168172A/ko not_active Ceased
- 2022-06-15 US US18/569,568 patent/US20240293369A1/en active Pending
- 2022-06-15 MX MX2023014357A patent/MX2023014357A/es unknown
- 2022-06-15 JP JP2023574504A patent/JP7668386B2/ja active Active
- 2022-06-15 PE PE2023003210A patent/PE20240241A1/es unknown
- 2022-06-15 AU AU2022294728A patent/AU2022294728A1/en not_active Abandoned
- 2022-06-15 CA CA3221533A patent/CA3221533A1/en active Pending
-
2023
- 2023-11-24 CL CL2023003513A patent/CL2023003513A1/es unknown
- 2023-11-24 CL CL2023003514A patent/CL2023003514A1/es unknown
- 2023-11-30 CO CONC2023/0016596A patent/CO2023016596A2/es unknown
- 2023-11-30 CO CONC2023/0016621A patent/CO2023016621A2/es unknown
- 2023-12-06 ZA ZA2023/11241A patent/ZA202311241B/en unknown
- 2023-12-06 ZA ZA2023/11237A patent/ZA202311237B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mercier et al. | 6% Hydroxyethyl starch (130/0.4) vs Ringer's lactate preloading before spinal anaesthesia for Caesarean delivery: the randomized, double-blind, multicentre CAESAR trial | |
| Lieberman et al. | A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia | |
| Riaz et al. | Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis | |
| Shemer | Update: medical treatment of onychomycosis | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| Chapple et al. | Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| CO2023016596A2 (es) | Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo | |
| AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
| Vlahovic et al. | Diagnosis and management of onychomycosis: perspectives from a joint podiatric medicine–dermatology roundtable | |
| Ross | Apixaban use among patients with severe renal impairment | |
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| C Nelson et al. | Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment | |
| BRPI0807940B8 (pt) | usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido | |
| BR112015030664A2 (pt) | combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos | |
| Yun et al. | Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia | |
| MX2024005237A (es) | Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo. | |
| MAHROSE et al. | Role of Ivabradine for Heart Rate Control in Management of Patients with Sepsis and Septic Shock | |
| TWI737972B (zh) | 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法 | |
| Gonon et al. | The combination of l‐arginine and ischaemic post‐conditioning at the onset of reperfusion limits myocardial injury in the pig | |
| MX2024014095A (es) | Suspension oral liquida de inhibidor de cinasa pan-raf | |
| Thampi et al. | Cosmetological competence of nail patches in combating onychomycosis-An approach to improve the quality of life | |
| BR112016014903A8 (pt) | combinações farmacêuticas que compreendem um inibidor de pi3k, seu uso, sua preparação combinada, e embalagem comercial | |
| BRPI0410266A (pt) | cristal, composto, processo para produzir um cristal, composição farmacêutica, inibidor de quinase, e, preventivo e/ou um remédio para doenças | |
| Ashraf et al. | Efficacy of Febuxostat for the Prevention of Progression of Chronic Kidney Disease in Hyperuricemia patients |